MD Anderson

Mutant KRAS and p53 Cooperate To Drive Pancreatic Cancer Metastasis

Preclinical research identifies CREB1 as new therapeutic target downstream of frequently mutated genes Researchers at The University of Texas MD Anderson Cancer Center have discovered that mutant KRAS and p53, the most frequently mutated genes in pancreatic cancer, interact through the CREB1 protein to promote metastasis and tumor growth. Blocking CREB1 in preclinical models reversed these effects and reduced metastases, suggesting an important new therapeutic target for the deadly cancer. The findings were published today in Cancer Discoveryand presented […]

MD Anderson’s Guillermina Lozano Elected to Fellows of the AACR Academy

Guillermina Lozano, Ph.D.

  Guillermina (Gigi) Lozano, Ph.D., chair of Genetics at The University of Texas MD Anderson Cancer Center, has been elected to the 2021 class of Fellows of the American Association for Cancer Research (AACR) Academy in recognition of her pioneering work to describe the p53 tumor suppressor pathway, which is undermined in many cancers. The mission of the AACR Academy is to recognize and honor distinguished scientists whose contributions have propelled significant innovation and progress against cancer. This year’s class of […]

Md Anderson’s Therapeutics Discovery Division, Orionis Biosciences Launch Project Helios To Advance Novel Small-Molecule Cancer Medicines

Collaboration designed to uncover new drug-target interactions at genome scale The University of Texas MD Anderson Cancer Center’sTherapeutics Discovery division and Orionis Biosciences today announced the launch of Project Helios, a research collaboration designed to unlock new drug development opportunities through genome-scale mapping of drug-target interactions. Combining Orionis’ unique high-throughput drug discovery technologies with the Therapeutics Discovery division’s expertise in small-molecule therapies and translational biology, Project Helios aims to create an unparalleled collection of drug-target interaction data to enable rational drug discovery, optimization […]

Focus Fund And Md Anderson Launch Investment Fund To Support Promising Investigational Cancer Therapies In Early-Stage Clinical Trials

Combination of over $50 million in committed capital along with access to cancer expertise and clinical facilities will help advance novel IND-ready candidates The Focus Fund GP, LLC, in partnership with The University of Texas MD Anderson Cancer Center, has launched Cancer Focus Fund, LP, an oncology-focused investment fund designed to support the advancement of compelling investigational cancer therapies from late preclinical development through Phase I and Phase Ib/II clinical trials. Small to midsize biopharmaceutical companies often […]